Please see the resources below to learn more about the issues surrounding the use of biosimilars.
June 10, 2014
On June 10, the National Alliance for Hispanic Health and twenty-two undersigned groups, representing millions of U.S. patients and professional caregivers involved in minority health, sent a letter to FDA urging for distinguishable names for biosimilars. Read More ›
June 3, 2014
On June 3, the National Organization for Rare Disorders (NORD) sent a letter to FDA Commissioner Hamburg advocating for distinguishable naming for biosimilars. Read More ›
May 20, 2014
On May 20, SWHR and 45 patient advocacy groups sent a letter urging FDA to consider gender-based Disparities in medical research and treatment when establishing an approach to biosimilar naming. Read More ›